A Prospective Randomized Clinical Trial of Combination Sequential Treatment With Y Peginterferon Alfa-2b and ETV (Entecavir) in CHB (Chronic Hepatitis B) Patients NAs (Nucleotides or Nucleosides) Experienced (Anchor Study)

Trial Profile

A Prospective Randomized Clinical Trial of Combination Sequential Treatment With Y Peginterferon Alfa-2b and ETV (Entecavir) in CHB (Chronic Hepatitis B) Patients NAs (Nucleotides or Nucleosides) Experienced (Anchor Study)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs Peginterferon alfa-2b (Primary) ; Adefovir; Entecavir; Granulocyte macrophage colony stimulating factor
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Acronyms ANCHOR
  • Most Recent Events

    • 24 Oct 2017 Interim results (n=101) assessing virological supression, presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases.
    • 11 Aug 2016 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.
    • 11 Aug 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top